Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding
[Display omitted] •IN-OT enhanced eating concern after 4–6 weeks of daily treatment during re-feeding.•The present study found IN-OT was well tolerated and safe.•Salivary cortisol levels were lower in anticipatory response to an afternoon snack.•Plasma OT levels did not change after chronic IN-OT or...
Gespeichert in:
| Veröffentlicht in: | Psychoneuroendocrinology 2018-01, Vol.87, p.83-92 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 92 |
|---|---|
| container_issue | |
| container_start_page | 83 |
| container_title | Psychoneuroendocrinology |
| container_volume | 87 |
| creator | Russell, Janice Maguire, Sarah Hunt, Glenn E. Kesby, Alice Suraev, Anastasia Stuart, Jordyn Booth, Jessica McGregor, Iain S. |
| description | [Display omitted]
•IN-OT enhanced eating concern after 4–6 weeks of daily treatment during re-feeding.•The present study found IN-OT was well tolerated and safe.•Salivary cortisol levels were lower in anticipatory response to an afternoon snack.•Plasma OT levels did not change after chronic IN-OT or with weight restoration.
Nutritional rehabilitation in anorexia nervosa (AN) is impeded by fear of food, eating and change leading to treatment resistance. Oxytocin (OT) exerts prosocial effects and modulates trust, fear, anxiety and neuroplasticity. The current placebo-controlled RCT examined the effects of intranasal oxytocin (IN-OT) in AN. The aim was to ascertain whether repeated doses of IN-OT enhance treatment outcomes in AN.
AN patients self-administered 36 IU IN-OT or placebo daily for 4–6 weeks during hospital treatment. The outcome measures were change in the Eating Disorders Examination (EDE) scale, weight gain, cognitive rigidity, social anxiety, obsessive and autistic symptoms. The effects of the first and last doses of IN-OT were assessed relative to placebo before and after a high-energy afternoon snack, to determine potential dampening of cortisol and anxiety levels by OT.
Weight gain was similar in both groups. The EDE eating concern subscale score was significantly lower after IN-OT treatment as was cognitive rigidity. There were no significant differences in social anxiety or any of the other outcomes at follow-up. After four weeks IN-OT, salivary cortisol levels were significantly lowered in anticipation of an afternoon snack compared to placebo. Morning plasma OT levels did not change after chronic IN-OT or with weight restoration.
IN-OT might enhance nutritional rehabilitation in AN by reducing eating concern and cognitive rigidity. Lower salivary cortisol levels in response to IN-OT suggest diminished neuroendocrine stress responsiveness to food and eating. Such effects require replication with inclusion of more sensitive subjective measures. |
| doi_str_mv | 10.1016/j.psyneuen.2017.10.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1954062962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306453017306340</els_id><sourcerecordid>1954062962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-3fd81a10a96880a359682633267d3239ff5b039c29d4ece251d3078e300e4d23</originalsourceid><addsrcrecordid>eNqFkE9LJDEQxcPioqPrV5Ac99JjJenOdDytyPoHBEG8h5hUuxm6kzFJi-On3wyje10oqKJ49R71I-SMwZIBk-fr5SZvA84YlhzYqi6XwNpvZMH6lWiEkHBAFiBANm0n4Igc57wGANlLfkiOuIJWKdEtyMtdKMkEk81I4_u2ROsDrVX-IC0JTZkwFBoHakJM-O4NDZjeYjYX9NEEFyf_gY7aWF3iONaxJF-t3Jx8eKEJmwHR1fEH-T6YMePpZz8hT9e_n65um_uHm7ury_vGtqItjRhczwwDo2TfgxFd7VwKweXKCS7UMHTPIJTlyrVokXfMCVj1KACwdVyckJ97202KrzPmoiefLY6jCRjnrJnqWpBcyZ1U7qU2xZwTDnqT_GTSVjPQO8Z6rb8Y6x3j3b4yrodnnxnz84Tu39kX1Cr4tRdgffTNY9LZegy2gkhoi3bR_y_jL20hkf0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1954062962</pqid></control><display><type>article</type><title>Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Russell, Janice ; Maguire, Sarah ; Hunt, Glenn E. ; Kesby, Alice ; Suraev, Anastasia ; Stuart, Jordyn ; Booth, Jessica ; McGregor, Iain S.</creator><creatorcontrib>Russell, Janice ; Maguire, Sarah ; Hunt, Glenn E. ; Kesby, Alice ; Suraev, Anastasia ; Stuart, Jordyn ; Booth, Jessica ; McGregor, Iain S.</creatorcontrib><description>[Display omitted]
•IN-OT enhanced eating concern after 4–6 weeks of daily treatment during re-feeding.•The present study found IN-OT was well tolerated and safe.•Salivary cortisol levels were lower in anticipatory response to an afternoon snack.•Plasma OT levels did not change after chronic IN-OT or with weight restoration.
Nutritional rehabilitation in anorexia nervosa (AN) is impeded by fear of food, eating and change leading to treatment resistance. Oxytocin (OT) exerts prosocial effects and modulates trust, fear, anxiety and neuroplasticity. The current placebo-controlled RCT examined the effects of intranasal oxytocin (IN-OT) in AN. The aim was to ascertain whether repeated doses of IN-OT enhance treatment outcomes in AN.
AN patients self-administered 36 IU IN-OT or placebo daily for 4–6 weeks during hospital treatment. The outcome measures were change in the Eating Disorders Examination (EDE) scale, weight gain, cognitive rigidity, social anxiety, obsessive and autistic symptoms. The effects of the first and last doses of IN-OT were assessed relative to placebo before and after a high-energy afternoon snack, to determine potential dampening of cortisol and anxiety levels by OT.
Weight gain was similar in both groups. The EDE eating concern subscale score was significantly lower after IN-OT treatment as was cognitive rigidity. There were no significant differences in social anxiety or any of the other outcomes at follow-up. After four weeks IN-OT, salivary cortisol levels were significantly lowered in anticipation of an afternoon snack compared to placebo. Morning plasma OT levels did not change after chronic IN-OT or with weight restoration.
IN-OT might enhance nutritional rehabilitation in AN by reducing eating concern and cognitive rigidity. Lower salivary cortisol levels in response to IN-OT suggest diminished neuroendocrine stress responsiveness to food and eating. Such effects require replication with inclusion of more sensitive subjective measures.</description><identifier>ISSN: 0306-4530</identifier><identifier>EISSN: 1873-3360</identifier><identifier>DOI: 10.1016/j.psyneuen.2017.10.014</identifier><identifier>PMID: 29049935</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Administration, Intranasal - methods ; Adult ; Anorexia nervosa ; Anorexia Nervosa - drug therapy ; Anxiety - drug therapy ; Controlled trial ; Cortisol ; Double-Blind Method ; Eating - drug effects ; Fear - drug effects ; Feeding Behavior - drug effects ; Female ; Humans ; Hydrocortisone - analysis ; Intranasal oxytocin ; Oxytocin - administration & dosage ; Oxytocin - pharmacology ; Placebo ; Saliva ; Stress</subject><ispartof>Psychoneuroendocrinology, 2018-01, Vol.87, p.83-92</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-3fd81a10a96880a359682633267d3239ff5b039c29d4ece251d3078e300e4d23</citedby><cites>FETCH-LOGICAL-c434t-3fd81a10a96880a359682633267d3239ff5b039c29d4ece251d3078e300e4d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0306453017306340$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29049935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Russell, Janice</creatorcontrib><creatorcontrib>Maguire, Sarah</creatorcontrib><creatorcontrib>Hunt, Glenn E.</creatorcontrib><creatorcontrib>Kesby, Alice</creatorcontrib><creatorcontrib>Suraev, Anastasia</creatorcontrib><creatorcontrib>Stuart, Jordyn</creatorcontrib><creatorcontrib>Booth, Jessica</creatorcontrib><creatorcontrib>McGregor, Iain S.</creatorcontrib><title>Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding</title><title>Psychoneuroendocrinology</title><addtitle>Psychoneuroendocrinology</addtitle><description>[Display omitted]
•IN-OT enhanced eating concern after 4–6 weeks of daily treatment during re-feeding.•The present study found IN-OT was well tolerated and safe.•Salivary cortisol levels were lower in anticipatory response to an afternoon snack.•Plasma OT levels did not change after chronic IN-OT or with weight restoration.
Nutritional rehabilitation in anorexia nervosa (AN) is impeded by fear of food, eating and change leading to treatment resistance. Oxytocin (OT) exerts prosocial effects and modulates trust, fear, anxiety and neuroplasticity. The current placebo-controlled RCT examined the effects of intranasal oxytocin (IN-OT) in AN. The aim was to ascertain whether repeated doses of IN-OT enhance treatment outcomes in AN.
AN patients self-administered 36 IU IN-OT or placebo daily for 4–6 weeks during hospital treatment. The outcome measures were change in the Eating Disorders Examination (EDE) scale, weight gain, cognitive rigidity, social anxiety, obsessive and autistic symptoms. The effects of the first and last doses of IN-OT were assessed relative to placebo before and after a high-energy afternoon snack, to determine potential dampening of cortisol and anxiety levels by OT.
Weight gain was similar in both groups. The EDE eating concern subscale score was significantly lower after IN-OT treatment as was cognitive rigidity. There were no significant differences in social anxiety or any of the other outcomes at follow-up. After four weeks IN-OT, salivary cortisol levels were significantly lowered in anticipation of an afternoon snack compared to placebo. Morning plasma OT levels did not change after chronic IN-OT or with weight restoration.
IN-OT might enhance nutritional rehabilitation in AN by reducing eating concern and cognitive rigidity. Lower salivary cortisol levels in response to IN-OT suggest diminished neuroendocrine stress responsiveness to food and eating. Such effects require replication with inclusion of more sensitive subjective measures.</description><subject>Administration, Intranasal - methods</subject><subject>Adult</subject><subject>Anorexia nervosa</subject><subject>Anorexia Nervosa - drug therapy</subject><subject>Anxiety - drug therapy</subject><subject>Controlled trial</subject><subject>Cortisol</subject><subject>Double-Blind Method</subject><subject>Eating - drug effects</subject><subject>Fear - drug effects</subject><subject>Feeding Behavior - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrocortisone - analysis</subject><subject>Intranasal oxytocin</subject><subject>Oxytocin - administration & dosage</subject><subject>Oxytocin - pharmacology</subject><subject>Placebo</subject><subject>Saliva</subject><subject>Stress</subject><issn>0306-4530</issn><issn>1873-3360</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9LJDEQxcPioqPrV5Ac99JjJenOdDytyPoHBEG8h5hUuxm6kzFJi-On3wyje10oqKJ49R71I-SMwZIBk-fr5SZvA84YlhzYqi6XwNpvZMH6lWiEkHBAFiBANm0n4Igc57wGANlLfkiOuIJWKdEtyMtdKMkEk81I4_u2ROsDrVX-IC0JTZkwFBoHakJM-O4NDZjeYjYX9NEEFyf_gY7aWF3iONaxJF-t3Jx8eKEJmwHR1fEH-T6YMePpZz8hT9e_n65um_uHm7ury_vGtqItjRhczwwDo2TfgxFd7VwKweXKCS7UMHTPIJTlyrVokXfMCVj1KACwdVyckJ97202KrzPmoiefLY6jCRjnrJnqWpBcyZ1U7qU2xZwTDnqT_GTSVjPQO8Z6rb8Y6x3j3b4yrodnnxnz84Tu39kX1Cr4tRdgffTNY9LZegy2gkhoi3bR_y_jL20hkf0</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Russell, Janice</creator><creator>Maguire, Sarah</creator><creator>Hunt, Glenn E.</creator><creator>Kesby, Alice</creator><creator>Suraev, Anastasia</creator><creator>Stuart, Jordyn</creator><creator>Booth, Jessica</creator><creator>McGregor, Iain S.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201801</creationdate><title>Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding</title><author>Russell, Janice ; Maguire, Sarah ; Hunt, Glenn E. ; Kesby, Alice ; Suraev, Anastasia ; Stuart, Jordyn ; Booth, Jessica ; McGregor, Iain S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-3fd81a10a96880a359682633267d3239ff5b039c29d4ece251d3078e300e4d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Intranasal - methods</topic><topic>Adult</topic><topic>Anorexia nervosa</topic><topic>Anorexia Nervosa - drug therapy</topic><topic>Anxiety - drug therapy</topic><topic>Controlled trial</topic><topic>Cortisol</topic><topic>Double-Blind Method</topic><topic>Eating - drug effects</topic><topic>Fear - drug effects</topic><topic>Feeding Behavior - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrocortisone - analysis</topic><topic>Intranasal oxytocin</topic><topic>Oxytocin - administration & dosage</topic><topic>Oxytocin - pharmacology</topic><topic>Placebo</topic><topic>Saliva</topic><topic>Stress</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Russell, Janice</creatorcontrib><creatorcontrib>Maguire, Sarah</creatorcontrib><creatorcontrib>Hunt, Glenn E.</creatorcontrib><creatorcontrib>Kesby, Alice</creatorcontrib><creatorcontrib>Suraev, Anastasia</creatorcontrib><creatorcontrib>Stuart, Jordyn</creatorcontrib><creatorcontrib>Booth, Jessica</creatorcontrib><creatorcontrib>McGregor, Iain S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychoneuroendocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Russell, Janice</au><au>Maguire, Sarah</au><au>Hunt, Glenn E.</au><au>Kesby, Alice</au><au>Suraev, Anastasia</au><au>Stuart, Jordyn</au><au>Booth, Jessica</au><au>McGregor, Iain S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding</atitle><jtitle>Psychoneuroendocrinology</jtitle><addtitle>Psychoneuroendocrinology</addtitle><date>2018-01</date><risdate>2018</risdate><volume>87</volume><spage>83</spage><epage>92</epage><pages>83-92</pages><issn>0306-4530</issn><eissn>1873-3360</eissn><abstract>[Display omitted]
•IN-OT enhanced eating concern after 4–6 weeks of daily treatment during re-feeding.•The present study found IN-OT was well tolerated and safe.•Salivary cortisol levels were lower in anticipatory response to an afternoon snack.•Plasma OT levels did not change after chronic IN-OT or with weight restoration.
Nutritional rehabilitation in anorexia nervosa (AN) is impeded by fear of food, eating and change leading to treatment resistance. Oxytocin (OT) exerts prosocial effects and modulates trust, fear, anxiety and neuroplasticity. The current placebo-controlled RCT examined the effects of intranasal oxytocin (IN-OT) in AN. The aim was to ascertain whether repeated doses of IN-OT enhance treatment outcomes in AN.
AN patients self-administered 36 IU IN-OT or placebo daily for 4–6 weeks during hospital treatment. The outcome measures were change in the Eating Disorders Examination (EDE) scale, weight gain, cognitive rigidity, social anxiety, obsessive and autistic symptoms. The effects of the first and last doses of IN-OT were assessed relative to placebo before and after a high-energy afternoon snack, to determine potential dampening of cortisol and anxiety levels by OT.
Weight gain was similar in both groups. The EDE eating concern subscale score was significantly lower after IN-OT treatment as was cognitive rigidity. There were no significant differences in social anxiety or any of the other outcomes at follow-up. After four weeks IN-OT, salivary cortisol levels were significantly lowered in anticipation of an afternoon snack compared to placebo. Morning plasma OT levels did not change after chronic IN-OT or with weight restoration.
IN-OT might enhance nutritional rehabilitation in AN by reducing eating concern and cognitive rigidity. Lower salivary cortisol levels in response to IN-OT suggest diminished neuroendocrine stress responsiveness to food and eating. Such effects require replication with inclusion of more sensitive subjective measures.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29049935</pmid><doi>10.1016/j.psyneuen.2017.10.014</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-4530 |
| ispartof | Psychoneuroendocrinology, 2018-01, Vol.87, p.83-92 |
| issn | 0306-4530 1873-3360 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1954062962 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Intranasal - methods Adult Anorexia nervosa Anorexia Nervosa - drug therapy Anxiety - drug therapy Controlled trial Cortisol Double-Blind Method Eating - drug effects Fear - drug effects Feeding Behavior - drug effects Female Humans Hydrocortisone - analysis Intranasal oxytocin Oxytocin - administration & dosage Oxytocin - pharmacology Placebo Saliva Stress |
| title | Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A34%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intranasal%20oxytocin%20in%20the%20treatment%20of%20anorexia%20nervosa:%20Randomized%20controlled%20trial%20during%20re-feeding&rft.jtitle=Psychoneuroendocrinology&rft.au=Russell,%20Janice&rft.date=2018-01&rft.volume=87&rft.spage=83&rft.epage=92&rft.pages=83-92&rft.issn=0306-4530&rft.eissn=1873-3360&rft_id=info:doi/10.1016/j.psyneuen.2017.10.014&rft_dat=%3Cproquest_cross%3E1954062962%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1954062962&rft_id=info:pmid/29049935&rft_els_id=S0306453017306340&rfr_iscdi=true |